Bio-Techne (NASDAQ:TECH) Releases Earnings Results, Misses Estimates By $0.02 EPS

Bio-Techne (NASDAQ:TECH) posted its quarterly earnings data on Wednesday. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.02), FiscalAI reports. The firm had revenue of $311.42 million for the quarter, compared to the consensus estimate of $316.11 million. Bio-Techne had a return on equity of 13.94% and a net margin of 6.67%.The firm’s quarterly revenue was down 1.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.56 earnings per share.

Here are the key takeaways from Bio-Techne’s conference call:

• Company reported a 2% organic revenue decline in Q3 but improved profitability with adjusted operating margin of 34.2%; management says the quarter faced ~400 bps of timing headwinds and that underlying organic growth was +2% excluding those items.
• Spatial biology (COMET) delivered >65% growth with a record backlog and the first COMET installed in China, positioning the platform for continued expansion.
• Excluding two Fast Track cell therapy customers, the GMP protein portfolio grew nearly 50% year-over-year, and Bio‑Techne plans to acquire the remainder of Wilson Wolf (G‑Rex bioreactors) by end of 2027 to bolster cell therapy manufacturing exposure.
• Emerging biotech spending remains the largest downside risk — revenues were weak (high-single-digit decline) despite recent strong funding trends, which management says typically take 2–3 quarters to translate into customer spending and expects a meaningful recovery in fiscal 2027.

Bio-Techne Stock Performance

Shares of TECH traded up $2.68 during mid-day trading on Thursday, reaching $50.08. The company’s stock had a trading volume of 3,261,109 shares, compared to its average volume of 2,442,511. Bio-Techne has a 1-year low of $45.12 and a 1-year high of $72.16. The stock has a market cap of $7.83 billion, a P/E ratio of 98.06, a PEG ratio of 3.73 and a beta of 1.41. The business has a 50-day simple moving average of $54.55 and a two-hundred day simple moving average of $59.61. The company has a current ratio of 4.54, a quick ratio of 3.08 and a debt-to-equity ratio of 0.13.

Bio-Techne Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Stockholders of record on Monday, May 18th will be given a $0.08 dividend. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, May 18th. Bio-Techne’s dividend payout ratio (DPR) is presently 62.75%.

Key Stories Impacting Bio-Techne

Here are the key news stories impacting Bio-Techne this week:

• Positive Sentiment: Wells Fargo cut its price target from $76 to $62 but reiterated an “overweight” rating — the bank still sees material upside from current levels, which can support buying interest. Wells Fargo lowers PT but keeps overweight
• Positive Sentiment: Board declared a quarterly cash dividend of $0.08/share (ex‑div May 18; payable May 29), returning cash to shareholders and making the stock modestly more attractive to income investors. Bio‑Techne Declares Dividend
• Positive Sentiment: Company expects Q4 organic growth to be approximately flat but is targeting roughly 100 basis points of margin expansion — a clear profit‑expansion objective that can help EPS even with muted revenue. Q4 outlook: flat organic growth, margin target
• Neutral Sentiment: GAAP EPS improved to $0.32 (from $0.14 a year ago) and operating margins expanded, while adjusted EPS dipped to $0.53; mixed profitability signals that some parts of the business are stabilizing even as others soften. Q3 fiscal 2026 results release
• Negative Sentiment: Q3 revenue missed estimates ($311.4M vs. ~$316.1M consensus) and reported a year‑over‑year decline (~1.5–2%), and adjusted EPS missed consensus by $0.02 — top‑line softness drove the initial selloff. Reuters: misses revenue estimates
• Negative Sentiment: Company cited demand headwinds from cuts to U.S. academic funding plus timing (prior‑year GMP fast‑track orders and delayed large Commercial Supply shipments) — these structural/ timing factors increase uncertainty around near‑term growth. Zacks: revenue & earnings miss, margin up

Institutional Trading of Bio-Techne

Hedge funds have recently made changes to their positions in the business. Measured Wealth Private Client Group LLC acquired a new stake in shares of Bio-Techne in the third quarter valued at approximately $32,000. iSAM Funds UK Ltd acquired a new stake in shares of Bio-Techne in the third quarter valued at approximately $33,000. Los Angeles Capital Management LLC acquired a new stake in shares of Bio-Techne in the fourth quarter valued at approximately $39,000. EverSource Wealth Advisors LLC lifted its holdings in Bio-Techne by 506.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 673 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 562 shares during the last quarter. Finally, Itau Unibanco Holding S.A. lifted its holdings in Bio-Techne by 81.5% during the 4th quarter. Itau Unibanco Holding S.A. now owns 1,009 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 453 shares during the last quarter. 98.95% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on TECH. TD Cowen reiterated a “buy” rating on shares of Bio-Techne in a report on Tuesday, March 17th. Zacks Research upgraded Bio-Techne from a “strong sell” rating to a “hold” rating in a research note on Monday, February 9th. Robert W. Baird set a $49.00 price target on Bio-Techne in a research note on Thursday. Weiss Ratings downgraded Bio-Techne from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Finally, UBS Group restated a “buy” rating and issued a $79.00 price target (up from $70.00) on shares of Bio-Techne in a research note on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $67.54.

About Bio-Techne

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.